TMC-Ag5 / Arjuna Therap - LARVOL DELTA

Ag5: A novel quantum cluster therapy targeting mitochondria and antioxidant systems in glioblastoma (EANO 2025) - "Ag5 has the potential to benefit a significant proportion of GBM patients. A clinical phase 0 neuro-oncology trial at University Hospitals Leuven, Belgium, is planned to test both the biomarker and therapeutic hypothesis for Ag5 in adult GBM patients."

Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Ag5: a novel quantum cluster therapy targeting mitochondria and antioxidant systems in glioblastoma (AACR 2025) - "Ag5 has the potential to benefit a significant proportion of GBM patients. A clinical phase 0 neuro-oncology trial at University Hospitals Leuven, Belgium, is planned to test both the biomarker and therapeutic hypothesis for Ag5 in adult GBM patients."

Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

The activity of therapeutic molecular cluster Ag5 is dependent on oxygen level and HIF-1 mediated signalling. (PubMed, Redox Biol) - "Importantly, the addition of Ag5 significantly increased radiation-induced cell death in hypoxic conditions associated with radioresistance. Together, these data demonstrate Ag5 is a potent and cancer specific agent which could be used effectively in combination with radiotherapy."

Journal • Oncology • Solid Tumor • HIF1A

Atomic Quantum Clusters of five atoms as Radiosensitizers in Cancer Therapy (EACR 2023) - "Radiation-induced DNA-damage was analysed by flow cytometry using the p-H2AX antibody.Results and DiscussionsAg5-AQCs treatment synergistically decreased colony formation when combined with photons, protons and CIRT in all the cell lines tested. Moreover, pretreatment with Ag5-AQCs do not increase DNA damage suggesting that Ag5-AQCs acts through a different cell death mechanism, using ROS generated by radiation to accelerate irreversible protein oxidation.ConclusionThe reported evidences suggest that the use of Ag5-AQCs in combination with RT provide a breakthrough for high ROS cancers and may improve RT efficacy without the need to increase the radiation doses."

Brain Cancer • CNS Tumor • Gastrointestinal Cancer • Glioblastoma • Hepatocellular Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Five silver atoms clusters enhance radiation sensitivity of pancreatic and glioblastoma cell lines (ESTRO 2023) - "Ag5, comprising clusters of five silver atoms, is a recently developed therapeutic agent that has been demonstrated to selectively kill cells with high levels of ROS by catalyzing the ROS-dependent oxidation of thiol groups on thioredoxins, peroxiredoxins and targets of the glutathione pathway (1)...Conclusion Our results demonstrate that targeting glutathione and thioredoxin pathways is a viable strategy to overcome radiation resistance ‘difficult to treat’ tumours such as PDAC and GBM. In vivo studies are planned to validate clinical potential."

Preclinical • Brain Cancer • CNS Tumor • Gastrointestinal Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Ag5 is highly potent, mitochondrially targeted agent with a differentiated mechanism of action that promises to be efficacious in solid cancers (AACR 2023) - "In summary, Ag5 is a novel and innovative therapeutic candidate shown to be safe and effective in preclinical studies. Based on experimental data with clinically relevant mutations, we hypothesize that Ag5 is ideally investigated in enriched patient populations of lung cancerand other solid cancers."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • ARID1A • KRAS • PRDX3